化疗序贯厄洛替尼治疗二线厄洛替尼耐药晚期非小细胞肺癌的临床疗效和安全性  

Treatment outcomes and safety of sequential administration of erlotinib following chemotherapy in patients with erlotinib(as second-line treatment)-resistant advanced non-small cell lung cancer

作　　者：于学娟[1,2] 张品良[2] 刘增军[2] 刘颖[2] 李明[2] 徐妮[2] 任瑞美[2] 

机构地区：[1]济南大学山东省医学科学院医学与生命科学学院,山东济南250022 [2]山东省肿瘤医院内六科,山东济南250117

出　　处：《肿瘤》2013年第11期1002-1007,共6页Tumor

摘　　要：目的：观察二线厄洛替尼耐药后应用化疗序贯厄洛替尼治疗晚期非小细胞肺癌的疗效和安全性。方法：回顾性分析30例ⅢB～Ⅳ期二线厄洛替尼耐药后缓慢进展的晚期非小细胞肺癌患者的资料，其中15例接受1个周期化疗（培美曲塞联合顺铂）后序贯厄洛替尼治疗（A组），另15例仅接受化疗（培美曲塞联合顺铂）（B组）。观察两组的近期疗效和不良反应，并进行生存分析。结果：A组和B组的客观缓解率分别为13.3%（2/15）和6.7%（1/15）（P＝1.000），疾病控制率分别为40.0%（6/15）和20.0%（3/15）（P＝0.426），中位无进展生存期分别为6.0和4.0个月（P＝0.001）。两组不良反应发生率差异无统计学意义。结论：化疗序贯厄洛替尼治疗二线厄洛替尼耐药晚期非小细胞肺癌患者具有较好的疗效，且不良反应可以耐受。Objective： To observe the therapeutic efficacy and safety of sequential administration of erlotinib. following chemotherapy in patients with erlotinib （as second-line treatment）-resistant advanced NSCLC （non-small cell lung cancer）. Methods： Thirty stages ⅢB-Ⅳ NSCLC patients with gradual progression after erlotinib treatment as second-line therapy were retrospectively reviewed. Of the 30 patinets, 15 patinets （group A） received one cycle of chemotherapy （pemetrexed plus cisplatin） followed by erlotinib, the remaining 15 patinets （group B） received chemotherapy alone （pemetrexed plus cisplatin）. The short-term response and side effects were observed and the survival was analyzed. Results： The objective response rates of group A and group B were 13.3% （2/15） and 6.7% （1/15）, respectively （P = 1.000）, and the disease control rates were 40.0% （6/15） and 20.0% （3/15）, respectively （P = 0.426）. The median progression-free survival of group A and group B were 6.0 and 4.0 months, respectively （P = 0.001）. There were no significant differences in the rates of side effects between the two groups. Conclusion： The administration of erlotinib following chemotherapy may offer benefits to the patients with erlotinib （as second-line treatment）-resistant advanced NSCLC. This treatment is also generally tolerable .

关 键 词：癌 非小细胞肺 厄洛替尼 抗肿瘤联合化疗方案 耐药 治疗结果 

分 类 号：R734.2[医药卫生—肿瘤]